Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01383538 · ClinicalTrials.gov registry record · Phase 1

FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma

A Phase 1 study of Pancreatic Cancer and Pancreatic Neoplasms, sponsored by Andrew Ko.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
3
Study locations

NCT01383538 is a Phase 1 study of Pancreatic Cancer and Pancreatic Neoplasms that has completed, run by Andrew Ko. The registered enrollment target is 15 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01383538, a Phase 1 study of Pancreatic Cancer and Pancreatic Neoplasms, has completed, sponsored by Andrew Ko.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this phase I study to determine the optimal dose for the combination of IPI-926 plus FOLFIRINOX (5-fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) chemotherapy in patients with pancreatic cancer.

Conditions Studied

Pancreatic Cancer Pancreatic Neoplasms Adenocarcinoma

Interventions

  • DRUG FOLFIRINOX, IPI-926

Study Locations (3)

California

  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Illinois

  • University of Chicago Comprehensive Cancer Center - Chicago

Wisconsin

  • University of Wisconsin Comprehensive Cancer Center - Madison

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2011-08-23
Est. Completion 2015-05-26
Phase Phase 1

Sponsor

Andrew Ko

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01383538

The ClinicalTrials.gov registry entry for NCT01383538 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Andrew Ko, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which FOLFIRINOX, IPI-926 is the first listed.

NCT01383538 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT01383538 about?

NCT01383538 is a clinical study titled "FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma". The purpose of this phase I study to determine the optimal dose for the combination of IPI-926 plus FOLFIRINOX (5-fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) chemotherapy in patients with pancreatic cancer.

What is the current status of trial NCT01383538?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2011-08-23. Estimated completion is 2015-05-26.

What conditions does trial NCT01383538 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Neoplasms, Adenocarcinoma.

What interventions are being tested in trial NCT01383538?

The interventions under investigation include: FOLFIRINOX, IPI-926 (DRUG).

Who is sponsoring clinical trial NCT01383538?

This trial is sponsored by Andrew Ko, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01383538 being conducted?

This trial has 3 study locations across California, Illinois, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

Pancreatic Neoplasms

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.